Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
OPILL is a norgestrel-based oral contraceptive tablet approved in 1973 for pregnancy prevention. It is a progestin-only pill (mini-pill) that works by altering cervical mucus and endometrial conditions to prevent fertilization. The product represents one of the earliest hormonal contraceptive options available to women.
With LOE approaching in July 2026, the brand is in terminal decline and likely operating with a minimal, cost-focused commercial infrastructure.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effects of Copper Versus Levonorgestrel Intrauterine Devices on Mucosal Microbiota and Barrier Function Among Young African Women
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on OPILL at Laboratoire Aguettant? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moOPILL offers limited career advancement opportunities due to its imminent loss of exclusivity and minimal commercial presence. Roles available are predominantly in managed decline, regulatory compliance, and transition management rather than growth-oriented brand building.